VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | The impact of biomarkers on pCR and survival in WSG ADAPT TP

Nadia Harbeck, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, discusses the predicative impact of biomarkers on pathological complete response (pCR) and survival in patients HER2+/HR+ early breast cancer. In the WSG TP phase II-trial, part of the ADAPT umbrella (NCT01779206), 375 patients received trastuzumab emtansine with or without endocrine therapy (ET), or trastuzumab with ET. Tumor-infiltrating lymphocytes (TILs) were not predicative of invasive disease-free survival (iDFS), whereas tumor immunogenicity was associated with improved outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Nadia Harbeck, MD, PhD, has received honoraria for lectures and/or consulting: Amgen, Astra Zeneca, Daiichi-Sankyo, Exact Sciences, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Seagen
Institution: Clinical phase II-IV trials
Other: Co-Director West German Study Group (WSG)

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter